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Abstract
Many genetically modified mouse strains are now available on a
C57BL/6 (H-2b) background, a strain that is relatively resistant
to collagen-induced arthritis. To facilitate the molecular
understanding of autoimmune arthritis, we characterised the
induction of arthritis in C57BL/6 mice and then validated the
disease as a relevant pre-clinical model for rheumatoid arthritis.
C57BL/6 mice were immunised with type II collagen using
different protocols, and arthritis incidence, severity, and
response to commonly used anti-arthritic drugs were assessed
and compared with DBA/1 mice. We confirmed that C57BL/6
mice are susceptible to arthritis induced by immunisation with
chicken type II collagen and develop strong and sustained T-cell
responses to type II collagen. Arthritis was milder in C57BL/6
mice than DBA/1 mice and more closely resembled rheumatoid
arthritis in its response to therapeutic intervention. Our findings
show that C57BL/6 mice are susceptible to collagen-induced
arthritis, providing a valuable model for assessing the role of
specific genes involved in the induction and/or maintenance of
arthritis and for evaluating the efficacy of novel drugs,
particularly those targeted at T cells.
Introduction
Rheumatoid arthritis (RA) is a highly inflammatory chronic pol-
yarthritis that causes joint destruction, deformity, and loss of
function. Sequelae include pain, disability, and increased mor-
tality. A role for CD4+ T cells in the pathogenesis of RA is
inferred from the strong HLA-DR association as well as the
large numbers of major histocompatability complex class II-
positive cells found in close proximity to activated CD4+ T cells
in inflamed joints. Furthermore, immunisation of transgenic
mice expressing RA-associated HLA-DR4/DR1 haplotypes
with type II collagen results in arthritis [1,2] and reveals a sin-
gle immunodominant epitope (amino acids 261 to 273) that
overlaps the immunodominant epitope in DBA/1 mice with col-
lagen-induced arthritis (CIA) (256 to 270) [1,3].
The identification of tumour necrosis factor-alpha (TNF-α) as a
key mediator of inflammation in RA has led to the development
of TNF-α-blocking biologics that control disease activity, but
there remains a need for therapies capable of modulating the
underlying immune response [4].
Pre-clinical assessment of therapeutics for RA has relied
largely on murine models of arthritis, particularly the CIA
model, in which mice are immunised with heterologous type II
collagen in complete Freund's adjuvant (CFA) [5]. The devel-
opment of CIA is strain-dependent, with H-2q and H-2r haplo-
types showing the greatest degree of susceptibility. The DBA/
1 strain (H-2q) is the most commonly used strain for pre-clini-
cal testing of potential anti-arthritic drugs and was success-
fully used to predict the beneficial effects of TNF-α blockade
[6,7]. However, although CIA in DBA/1 mice has been
extremely useful for testing drugs with anti-inflammatory prop-
erties, its usefulness for assessing T cell-targeted therapies is
limited to some extent by the relatively acute nature of the
disease.
CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; IFN-γ = interferon-gamma; IL = 
interleukin; LNC = lymph node cell; mAb = monoclonal antibody; RA = rheumatoid arthritis; TNF-α = tumour necrosis factor-alpha.Arthritis Research & Therapy    Vol 9 No 5    Inglis et al.
Page 2 of 8
(page number not for citation purposes)
A further limitation of the classic CIA model in DBA/1 mice is
that most transgenic and knockout strains of mice are on a
C57BL/6 (B6) background (H-2b), which is regarded to be rel-
atively resistant to arthritis induction when bovine type II colla-
gen is used as an immunogen [8,9]. To circumvent this
problem, genetically modified strains have generally been
backcrossed for a minimum of eight generations onto the
DBA/1 background, which introduces a delay of 1 to 2 years.
However, it has been reported that, contrary to previous find-
ings, B6 mice are indeed susceptible to arthritis induced by
chicken type II collagen [10-12], although many groups have
been unable to induce arthritis in this strain in a reproducible
manner [8].
The primary aims of this project were to characterise CIA in the
C57BL/6 mouse clinically and histologically and to analyse
cellular and humoral immune responses to type II collagen dur-
ing the course of the disease. We show that B6 mice develop
a chronic form of CIA and that this model closely resembles
human RA in terms of its disease course, histological findings,
and in its response to commonly used anti-arthritic drugs. We
also show that B6 mice develop a sustained T-cell response
to chicken collagen as well as to autologous (mouse) collagen.
Materials and methods
Purification of type II collagen
Bovine collagen was purified from articular cartilage, and
mouse and chicken collagens were purified from non-articular
(sternal) cartilage. All collagens were prepared by pepsin
digestion and salt fractionation according to established pro-
cedures [13]. Lathyritic rat type II collagen (a gift from Lars
Klareskog, formerly of Uppsala, Sweden) was prepared with-
out pepsin.
Induction and assessment of arthritis
Ten- to 12-week-old male mice were used for all procedures,
were housed in groups of 10, and were maintained at 21°C ±
2°C on a 12-hour light/dark cycle with food and water ad libi-
tum. All experimental procedures were approved by the local
ethical review process committee and the UK Home Office.
DBA/1 mice were bred at the Kennedy Institute of Rheumatol-
ogy (London, UK) and B6 mice were purchased from Harlan
UK (Bicester, Oxfordshire, UK). To reduce the risk of fighting
amongst males, mice from different cages were not mixed
beyond 6 weeks of age. All mice were immunised intradermally
in two sites at the base of the tail with 200 μg of bovine,
chicken, or mouse type II collagen in CFA as described previ-
ously [13]. To prepare the CFA, 100 mg of desiccated killed
Mycobacterium tuberculosis H37Ra (BD Biosciences,
Oxford, Oxfordshire, UK) was ground with a pestle and mortar
to produce a fine powder and then suspended in 30 mL of
incomplete Freund's adjuvant (BD Biosciences). It was
observed that fighting amongst male mice reduced the inci-
dence of arthritis. Hence, to reduce the risk of fighting, mice
from different cages were not mixed beyond 6 weeks of age.
Each experiment was performed on a minimum of two
occasions.
For macroscopic assessment of arthritis, the thickness of each
affected hind paw was measured daily with microcalipers
(Kroeplin GmbH, Schlüchtern, Germany) and the diameter
was expressed as an average for inflamed hind paws per
mouse. Animals were also scored for clinical signs of arthritis
[13] as follows: 0 = normal, 1 = slight swelling and/or ery-
thema, 2 = pronounced oedematous swelling, and 3 = joint
rigidity. Each limb was graded thus, allowing a maximum score
of 12 per mouse. After completion of the experiment, mice
were sacrificed and hind paws were immersion-fixed in 10%
(vol/vol) buffered formalin and decalcified with 5.5% EDTA
(ethylenediaminetetraacetic acid) in buffered formalin.
For histological assessment of arthritis, arthritic mice were
killed up to 2 weeks after disease onset (early arthritis, n = 8)
or 6 to 8 weeks following onset (late arthritis, n = 8). Joints
were decalcified and paraffin-embedded, and sections (10
μm) were stained (haematoxylin and eosin) for conventional
histology. Joints were classified according to the presence or
absence of inflammatory cell infiltrates (defined as focal accu-
mulations of leukocytes). Histological analysis was performed
in a blinded fashion by a trained histopathologist (AS) (N = 8
per point).
Analysis of antibody production
Anti-collagen antibody isotypes were assessed in the serum of
mice with early or late arthritis. Enzyme-linked immunosorbent
assay (ELISA) plates (Thermo Fisher Scientific, Rochester,
NY, USA) were coated with 5 μg/mL of type II collagen dis-
solved in Tris buffer (0.05 M Tris, containing 0.2 M NaCl, pH
7.4), blocked with 2% bovine serum albumin, and then incu-
bated with serial dilutions of test sera. A standard curve was
created for each assay by including serial dilutions of a refer-
ence sample on each plate. The reference sample was arbi-
trarily assigned an antibody concentration of 1 AU/mL. Bound
IgG1 or IgG2a/c was detected by incubation with horseradish
peroxidase-conjugated sheep anti-mouse IgG1 (BD Bio-
sciences), or an antibody that recognises both IgG2a and
IgG2c (BD Biosciences), followed by TMB (3,3', 5,5'-tetrame-
thylbenzidine) substrate. Optical density was measured at 450
nm. Antibody concentrations for each serum sample were
obtained by reference to the standard curve (N = 8 per point).
Analysis of T-cell activity
Inguinal lymph nodes were excised from mice with early or late
arthritis. Lymph node cells (LNCs) were cultured in RPMI
1640 containing foetal calf serum (10% vol/vol), 2-mercap-
toethanol (20 μM), L-glutamine (1% wt/vol), penicillin (100 U/
mL), and streptomycin (100 μg/mL) in the presence or
absence of type II collagen or the synthetic collagen fragment
CII256-270 (both at 50 μg/mL). After 48 hours, 100 μL of cul-
ture medium was carefully removed for measurement ofAvailable online http://arthritis-research.com/content/9/5/R113
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cytokines and the remaining cells were pulsed with 1 μCi 3H
thymidine per well for a further 18 hours. Cells were then har-
vested and plates were assessed for 3H thymidine incorpora-
tion. Each assay was performed on a minimum of three
occasions. Secreted interferon-gamma (IFN-γ), interleukin (IL)-
5, and IL-10 were measured in the culture supernatant by
sandwich ELISA using capture and detection antibody pairs
(BD Biosciences).
Drug therapy
The therapeutic responses of arthritic B6 and DBA/1 mice to
intraperitoneal administration of dexamethasone (0.5 mg/kg
daily), anti-TNF monoclonal antibody (mAb) (TN3-19.12; 300
μg every 3 days), methotrexate (0.75 mg/kg every 3 days), or
indomethacin (2.5 mg/kg daily) were assessed. The therapeu-
tic response was defined as the percentage reduction in clini-
cal score following 10 days of therapy relative to mice treated
with vehicle alone. Each experiment was performed twice.
Statistical analysis
Statistical analysis was performed by one-way analysis of var-
iance followed by Dunnett multiple comparisons test, where
appropriate.
Results
Induction of arthritis in B6 mice
We first compared bovine, chicken, and mouse collagen type
II for their ability to induce arthritis in B6 mice (Table 1). Only
chicken collagen was able to induce arthritis in B6 mice, with
a maximum incidence of 61.7% and mean day of onset of 29.4
± 1.3 days after primary immunisation. This is in contrast to
DBA/1 mice, in which collagen from all species induced arthri-
tis (Table 1). We then compared the clinical progression of
arthritis in B6 mice with our standard CIA in DBA/1 mice,
immunised with bovine CII. Hind paw swelling was assessed
up to 120 days after immunisation. Paw swelling in B6 mice
was significantly less than in DBA/1 mice on day 21 after
immunisation but was significantly greater on day 120 after
immunisation (Figure 1a). However, clinical scores of DBA/1
mice with CIA were higher than those of B6 mice, indicating
that arthritis was milder in B6 mice than DBA/1 mice (Figure
1b).
To assess the histological outcome in the two models, hind
paws were fixed, sectioned, and stained with haematoxylin and
eosin. In the early stages of CIA, inflammatory infiltrates were
found in both the DBA/1 (Figure 2a) and B6 (Figure 2b) joints.
However, at late stages of disease, only 37.5% of DBA/1 mice
studied had inflammatory infiltrates (Figure 2c,e). In contrast,
100% of B6 joints studied had inflammatory infiltrates in both
early and late arthritis (Figure 2d,f).
Comparison of anti-collagen IgG profiles in B6 and DBA/
1 mice
Circulating anti-collagen IgG1 and IgG2a/c isotypes were
assessed by ELISA (Figure 3). At early stages of disease (up
to 2 weeks after onset), the two strains of mice had similar lev-
els of collagen-specific IgG1 (Figure 3a) and IgG2a/c (Figure
3b). In late disease (6 to 8 weeks after onset), titres of both
IgG1 and IgG2a/c had increased modestly in DBA/1 mice. In
contrast, in late stages of disease, levels of IgG1 had fallen,
whereas levels of IgG2a/c had risen dramatically in B6 mice,
indicating a predominant Th1 immune response.
T-cell responses in B6 and DBA/1 mice
To further investigate the T-cell responses in the different
strains, LNCs were isolated from DBA/1 and B6 mice before
immunisation, up to 2 weeks after disease onset (early arthri-
tis), or 6 to 8 weeks after onset (late arthritis). Assessment of
proliferation and IFN-γ production in response to collagen of
different species in vitro revealed that LNCs from B6 and
DBA/1 mice with either early or late arthritis responded to
Figure 1
Collagen-induced arthritis (CIA) in B6 and DBA/1 mice Collagen-induced arthritis (CIA) in B6 and DBA/1 mice. Mice were immunised with type II collagen in complete Freund's adjuvant, and paw diameter 
(a) and clinical score (b) were measured for 120 days (n = 10 arthritic mice per group). (a) Paw swelling reached a peak in DBA/1 mice on day 30 
and declined thereafter. In contrast, in B6 mice, paw swelling, although less pronounced, remained elevated up to day 120. **P < 0.01. (b) The clin-
ical score was less in B6 CIA than DBA/1 CIA throughout most of the period studied. *P < 0.05.Arthritis Research & Therapy    Vol 9 No 5    Inglis et al.
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Table 1
Incidence, mean day of onset, and maximum clinical score of B6 and DBA/1 mice with collagen-induced arthritis
Species of CII used for immunisation
Bovine Chicken Mouse
DBA/1 C57BL/6 DBA/1 C57BL/6 DBA/1 C57BL/6
Incidence 94 0 96 61 30 0
Mean day of onset 24.4 ± 1.9 0 18.3 ± 2.5 29.4 ± 1.3 81.7 ± 11.5 0
Maximum clinical score 4.3 ± 0.9 0 5.8 ± 2.3 3.1 ± 2.2 2.6 ± 1.0 0
There were 20 or more mice per group (data pooled from three independent experiments).
Figure 2
Chronic inflammatory infiltrate in B6 mice with collagen-induced arthritis Chronic inflammatory infiltrate in B6 mice with collagen-induced arthritis. Histological assessment of arthritis was carried out in early arthritis (up to 2 
weeks after onset, n = 8) and late arthritis (6 to 8 weeks after onset, n = 8). (a) Severe joint destruction with massive accumulation of polymorpho-
nuclear cells (PMNs) was observed in DBA/1 in early arthritis. (b) In B6 mice, the infiltrating cells were predominantly mononuclear in early arthritis 
and there was less joint erosion. (c) In late arthritis, the inflammatory response largely resolved in DBA/1 mice, although the joint destruction was not 
reversed. (d) The inflammatory response remained active in B6 mice in late arthritis and there was progressive joint erosion. Original magnification, 
× 100. (e) The numbers of joints showing foci of inflammatory cells (lymphocytes and PMNs) in the joint were compared in early and late arthritis. 
**P < 0.01.Available online http://arthritis-research.com/content/9/5/R113
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chicken, bovine, and mouse CII (Figure 4a,b). Of particular
note were the strong proliferative and cytokine responses to
autologous (mouse) collagen in the LNC cultures from B6
mice, providing evidence of autoimmunity at the T-cell level.
However, LNCs from arthritic B6 mice failed to respond to the
collagen peptide CII256-270 (which represents the immuno-
dominant epitope recognised by T cells from DBA/1 mice in
the context of I-Aq), whereas LNCs from DBA/1 mice were
responsive (data not shown). This indicates differences in the
T-cell epitope specificities between the two strains. IL-5 and
IL-10 were not detected in the cultures (data not shown).
It has been reported that pepsin contamination contributes to
the high levels of T-cell reactivity observed in some strains of
mouse and rat immunised with pepsin-digested collagen [14].
To assess the contribution of pepsin to the anti-collagen T-cell
response in B6 mice, we compared the responses of LNCs
from arthritic B6 mice to lathyritic pepsin-free rat collagen and
to pepsin-digested rat collagen [15] (Figure 4c). Proliferative
responses to rat collagen were similar irrespective of whether
pepsin was used for digestion. We therefore concluded that
the T cells from B6 mice were responding specifically to colla-
gen and not to contaminating pepsin.
Validation of the B6 model for therapeutic studies
We next assessed the therapeutic profile of arthritic B6 mice
to drugs commonly used to treat RA, including a corticosteroid
(dexamethasone), a TNF-blocking biologic (anti-TNF mAb), a
disease-modifying anti-rheumatic drug (methotrexate), and a
nonsteroidal anti-inflammatory drug (indomethacin). Clinical
score was assessed, as a measure of spread of disease pro-
gression. As expected, dexamethasone and anti-TNF mAb
gave clear reductions in clinical score of at least 75% and
50%, respectively, following 10 days of therapy in both DBA/
1 and B6 mice with CIA (Figure 5). In contrast, whereas meth-
otrexate reduced clinical score in arthritic B6 mice by 50%, no
significant effect on disease severity was observed in arthritic
DBA/1 mice (Figure 5). Likewise, as previously reported,
indomethacin reduced clinical score in the DBA/1 mouse by
more than 50% but had no significant effect in B6 mice, indi-
cating that it does not alter progression of the disease in this
model, as occurs in human RA.
Discussion
The model of CIA, a T cell- and cytokine-dependent disease,
in DBA/1 mice has led to increased understanding of RA and
has facilitated the development of novel biologics, such as
TNF-blocking therapies [16]. However, the apparent resist-
ance of strains normally used to carry modified genes has
impeded our ability to rapidly ask basic questions about dis-
ease pathogenesis, as a 1- to 2-year backcross to DBA/1
mice is needed. Our aim was to comprehensively assess the
susceptibility of B6 mice to CIA and compare the disease with
the 'classic' model in DBA/1 mice.
Our studies showed that chicken, and not bovine, CII was
capable of inducing disease in B6 mice, with an incidence of
50% to 75%, an incidence similar to that previously described
[10-12]. This is in contrast to DBA/1 mice, in which bovine,
mouse, and chicken CII all induced disease, with an incidence
of 80% to 100%. This may account for reports of resistance
to CIA in B6 mice, in which bovine CII was used for immunisa-
tion [8]. Other confounding factors could include the quality of
collagen preparation, or substrains of B6 mice, and it is impor-
tant to note that our study was carried out with B6 mice pur-
chased from Harlan UK, although we have obtained similar
results with B6 mice from Charles River UK Ltd. (Margate,
Kent, UK).
The phenotype of arthritis was milder in B6 mice than in DBA/
1 mice, with less swelling and a more gradual increase in clin-
ical score. Histological assessment of the hind paws from
arthritic DBA/1 and B6 mice revealed that, in early arthritis (up
to 2 weeks after onset), there was a similar degree of inflam-
matory cell infiltration in the two strains. In contrast, in late
arthritis (6 to 8 weeks after onset), inflammatory cell infiltration
Figure 3
Comparison of anti-collagen IgG isotypes in DBA/1 and B6 mice with collagen-induced arthritis Comparison of anti-collagen IgG isotypes in DBA/1 and B6 mice with collagen-induced arthritis. Serum from naïve and arthritic mice were analysed 
for anti-collagen antibodies. IgG1 (a) and IgG2a/c (b) anti-collagen isotypes were quantified in naïve mice and mice with early (up to 2 weeks after 
onset) and late (6 to 8 weeks after onset) arthritis after immunisation (n = 8). *P < 0.05, **P < 0.01.Arthritis Research & Therapy    Vol 9 No 5    Inglis et al.
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was reduced in DBA/1 mice compared with B6 mice, although
it remains to be established which cell types are present in the
joints of B6 CIA.
Assessment of lymph node responses showed that in the B6
mouse, both early and late after immunisation, proliferation and
IFN-γ production in response to collagen occurred. Also of
note, a strong response was observed in B6 mice to mouse
collagen, suggesting the autoimmune nature of the model. It
must be noted that bovine and murine collagen did not induce
arthritis in B6 mice.
The reason why chicken, and not mouse or bovine, CII is arthri-
togenic in B6 mice is presumably due to recognition by B6 T
cells of a peptide of chicken CII in the context of H-2b class II
molecules. This suggests that differences in the amino acid
sequence between chicken and mouse/bovine CII are
required to break tolerance and induce arthritis. It is intriguing
that the T-cell response was greater and more sustained in B6
mice compared with DBA/1 mice, but the reasons for this are
unknown. The number and activity of CD4+CD25+ regulatory
T cells were found to be similar in the two strains (G. Criado,
M. Medghalchi, R.O. Williams, unpublished observations).
Therefore, we cannot attribute sustained T-cell responses to
any obvious defect in regulatory T cells in B6 mice.
It has been proposed that pepsin (used to purify collagen)
plays an important role in breaking T-cell tolerance to collagen
and that much of the T-cell response in some strains of mice
and rat is directed against pepsin or pepsin-modified epitopes
of collagen [14]. By showing equivalent responses to CII pre-
pared with and without pepsin using lathyritic collagen [14],
we have shown that the T-cell response is not dependent on
pepsin in this model, in contrast to rat strains, in which T-cell
Figure 4
Sustained T-cell responses to collagen type II in B6 mice with collagen- induced arthritis Sustained T-cell responses to collagen type II in B6 mice with collagen-
induced arthritis. Inguinal lymph node cells were cultured from naïve 
mice or mice with early (up to 2 weeks after onset) or late (6 to 8 weeks 
after onset) arthritis (n = 8). Cells were cultured for 72 hours with 
bovine, chicken, and murine collagen type II. (a) Proliferation was 
assessed by 3H thymidine incorporation. (b) Interferon-gamma (IFN-γ) 
secretion was assessed in the culture supernatant by enzyme-linked 
immunosorbent assay. (c) Proliferative responses of T cells from colla-
gen-immunised B6 mice to type II collagen purified with or without pep-
sin were compared. Responses to chicken collagen and anti-CD3 
monoclonal antibody were also measured. Proliferation was assessed 
by 3H thymidine incorporation. ***P < 0.001. N.S., not significant.
Figure 5
Collagen-induced arthritis in B6 mice is a valid model for testing anti- arthritic compounds Collagen-induced arthritis in B6 mice is a valid model for testing anti-
arthritic compounds. Arthritic B6 or DBA/1 mice were treated from the 
time of onset of arthritis with dexamethasone (Dex) (0.5 mg/kg per day), 
anti-tumour necrosis factor (TNF) monoclonal antibody (300 μg every 3 
days), methotrexate (MTX) (0.75 mg/kg every 3 days), or indomethacin 
(Indo) (2.5 mg/kg daily) or the relevant vehicle. After 10 days of therapy, 
the clinical score was assessed and expressed as a percentage of vehi-
cle-treated mice (n = 8 per group). Experiments were repeated twice. 
Data shown are from one representative study. *P < 0.05, **P < 0.01, 
***P < 0.001. NS, not significant.Available online http://arthritis-research.com/content/9/5/R113
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responses have been shown to be directed mainly against
contaminating pepsin [15]. However, we cannot exclude the
possibility that pepsin contributes to the breaking of tolerance
during immunisation, and we were unable to obtain lathyritic
chicken type II collagen in order to test this hypothesis. How-
ever, the mycobacterial component of CFA provides many
factors that are able to break tolerance via activation of Toll-like
receptors.
The therapeutic profile of CIA in the B6 mouse was similar to
that of RA, with a therapeutic action of methotrexate at a dose
comparable to human therapy. This is in contrast to CIA in
DBA/1 mice, in which methotrexate had no effect. One of the
anti-inflammatory mechanisms of methotrexate is thought to
be due to increased adenosine production [17]. Adenosine
acts via G-protein-coupled receptors to increase cAMP levels,
which is known to reduce inflammation [18]. It was recently
reported that DBA/1 mice, but not B6 mice, are genetically
resistant to the effects of methotrexate, due to defective ade-
nosine accumulation [19]. This is of particular significance as
methotrexate is now regarded as the 'gold standard' small-
molecular-weight drug for RA and is frequently used in combi-
nation with biologics, such as anti-TNF therapy [20]. There is,
therefore, an increasing need to model the anti-arthritic effects
of methotrexate in combination with other therapies in order to
optimise treatment regimens and to identify possible interac-
tions. Likewise, indomethacin did not slow the disease pro-
gression of CIA in B6 mice, as in RA, but significantly reduced
the disease severity of CIA in DBA/1 mice [21].
Conclusion
In summary, we have confirmed that inflammatory, destructive
arthritis can be induced reproducibly in the B6 mouse using
chicken type II collagen. The disease in B6 mice is milder, but
more chronic, with more pronounced and more persistent T-
cell responses. The maintained presence of inflammatory cell
infiltrate and the response of the disease in B6 mice to anti-
arthritic drugs such as methotrexate show a good correlation
with human RA. We therefore propose that this model will be
useful for testing new therapeutics, especially directed against
T cells, in addition to investigating mechanisms of action of
current therapies such as methotrexate.
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